Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.

@article{Holzinger2012GenomewideAS,
  title={Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.},
  author={Emily R. Holzinger and Benjamin J. Grady and Marylyn DeRiggi Ritchie and Heather Ribaudo and Edward P. Acosta and Gene D. Morse and Roy M. Gulick and Gregory K. Robbins and David B. Clifford and Eric S Daar and Paul Mclaren and David W. Haas},
  journal={Pharmacogenetics and genomics},
  year={2012},
  volume={22 12},
  pages={858-67}
}
OBJECTIVES Prior candidate gene studies have associated CYP2B6 516G→T [rs3745274] and 983T→C [rs28399499] with increased plasma efavirenz exposure. We sought to identify novel variants associated with efavirenz pharmacokinetics. MATERIALS AND METHODS Antiretroviral therapy-naive AIDS Clinical Trials Group studies A5202, A5095, and ACTG 384 included plasma sampling for efavirenz pharmacokinetics. Log-transformed trough efavirenz concentrations (Cmin) were previously estimated by population… CONTINUE READING
34 Citations
38 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Effect of CYP 2 B 6 , ABCB 1 , and CYP 3 A 5 polymorphisms on efavirenz pharmacokinetics and treatment response : an AIDS Clinical Trials Group study

  • HJ Ribaudo, H Liu, M Schwab, E Schaeffeler, M Eichelbaum, AA Motsinger-Reif
  • J Infect Dis
  • 2010

Similar Papers

Loading similar papers…